Latest
seekingalpha.com
· about 23 hours ago
Snam S.p.A. (SNMRY) Q2 2026 Earnings Call Transcript
Snam S.p.A. (SNMRY) Q2 2026 Earnings Call Transcript
Market narrative
Read the headlines around the signals.
Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.
Stocks
More recent coverage
Vinci SA (VCISY) Q2 2026 Earnings Call Transcript
Vinci SA (VCISY) Q2 2026 Earnings Call Transcript
Erste Bank Polska S.A. (BKZHF) Q2 2026 Earnings Call Transcript
Erste Bank Polska S.A. (BKZHF) Q2 2026 Earnings Call Transcript
POSCO Holdings Inc. (PKX) Q2 2026 Earnings Call Transcript
POSCO Holdings Inc. (PKX) Q2 2026 Earnings Call Transcript
Ilika plc (ILIKF) Q4 2026 Earnings Call Transcript
Ilika plc (ILIKF) Q4 2026 Earnings Call Transcript
Kaplan Fox Notifies Cogent Communications Holdings, Inc. (CCOI) Investors of a Securities Class Action Deadline on September 21, 2026
New York, New York--(Newsfile Corp. - August 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Cogent Communications Holdings, Inc. ("Cogent" or the "Company") (NASDAQ: CCOI) on behalf of investors that purchased or otherwise acquired Cogent securities between February 29, 2024 and May 1, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Cogent and have suffered losses, you may CLICK HERE to contact us.
247wallst.com
· about 23 hours ago
Raising the Retirement Age to 69 Could Force Millions to Claim Social Security Early, and Lock in Smaller Checks
Congress is weighing a change to Social Security that could quietly shrink retirement checks for millions of future retirees, hitting blue-collar workers the hardest. The tradeoffs buried in this proposal are more complicated than most people realize.
Applied Materials: July Purged Positioning, Not The Thesis
Applied Materials (AMAT) delivered record Q2 FY2026 revenue of $7.91B (+11% Y/Y) and non-GAAP EPS of $2.86 (+20% Y/Y). Management raised CY2026 equipment growth guidance to 30%+, with improved order visibility and strong DRAM and AGS segment performance. Despite a ~40% drawdown from highs, fundamentals remain robust, and the recent correction is attributed to sector positioning rather than company weakness.
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (FDA) has cleared the company's Phase 2b registration-enabling clinical trial for SkinJect in patients with Gorlin syndrome, representing an important regulatory milestone for its lead investigational asset. Speaking with Proactive, CEO Raza Bokhari said the FDA had approved the company's proposed study following discussions and feedback, allowing Medicus Pharma (NASDAQ:MDCX) to move ahead with a crossover registration study involving up to 50 patients.
FUTU DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Futu Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FUTU
New York, New York--(Newsfile Corp. - August 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Futu Holdings Limited (NASDAQ: FUTU) between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"), of the important August 25, 2026 lead plaintiff deadline. SO WHAT: If you purchased Futu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Skyworks Solutions Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Skyworks Solutions, Inc. - SKW
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Skyworks Solutions, Inc. (NasdaqGS: SKW) (“Skyworks” or the “Company”). On February 5, 2025, the Company announced its financial results for the first quarter of fiscal year 2025, disclosing lower-than anticipated revenue guidance for the second quarter of fiscal year 202.
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.
Is Bloom Energy in Its Nvidia Moment?
Bloom Energy reported stellar results for the second quarter of 2026, surpassing $1 billion in quarterly revenue for the first time. The energy technology company also reported a profit of $196.2 million.
Meta Is Paying Workers to Learn a Trade. For Someone Near 60, the Real Prize May Be Delaying Social Security.
Meta's free trades program promises laid-off workers a guaranteed job offer, but for someone closing in on 60, the most valuable thing those wages could buy has nothing to do with the work itself.
Lisa Martin: Big Tech Earnings & MSFT Role as a Hyperscaler Benchmark
Lisa Martin breaks down this quarter's Big Tech earnings, explaining why investor reactions are driven as much by expectations and timing as the results themselves. She discusses how hyperscalers are being held to a higher standard, why Microsoft's (MSFT) earnings helped calm concerns that emerged after Alphabet's (GOOGL) report, and how Microsoft has become a benchmark for both cloud computing and AI.
prnewswire.com
· about 23 hours ago
DELLA Celebrates 14th Anniversary with Annual DELLA Day and Announces New Build Your Own System Experience
/PRNewswire/ -- DELLA, a home comfort brand specializing in ductless mini split systems and heating and cooling solutions, today announced the return of DELLA
Microsoft Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Microsoft Corporation - MSFT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ), announces that K
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a concentrated basket of 30 biotech firms, whereas State Street Health Care Select Sector SPDR ETF provides exposure to 60 broad healthcare companies State Street Health Care Select Sector SPDR ETF has experienced a shallower maximum drawdown and lower volatility than Invesco Biotechnology & Genome ETF over the last five years
Microsoft Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Microsoft Corporation - MSFT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Microsoft Corporation (“Microsoft” or the “Company”) (NasdaqGS: MSFT). In recent years, Microsoft's cloud computing platform, known as Azure, has been its main growth driver providing customers with computing, networking, storage, mobile and web application services, arti.
Nomura Real Estate Holdings, Inc. (NMEHF) Q1 2027 Earnings Call Prepared Remarks Transcript
Nomura Real Estate Holdings, Inc. (NMEHF) Q1 2027 Earnings Call Prepared Remarks Transcript